News

Medical Dialogues23m

Type II cryoglobulinemic vasculitis associated with poor prognosis in patients with Sjögren disease: JAMA

A new study published in the Journal of American Medical Association showed that Type II cryoglobulinemic vasculitis was the ...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...
Fierce Pharma4d

RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study in China

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...
Fierce Biotech6d

Novartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...
University at Buffalo3d

UB dental professor studying immune system’s role in Sjögren’s disease

Jill M. Kramer, DDS, PhD, associate professor in the Department of Oral Biology at the University at Buffalo School of Dental ...
Rheumatology Advisor2d

Ianalumab Reduces Sjögren Disease Activity in Late Stage Trials

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.